Pregled bibliografske jedinice broj: 1087424
The efficacy and safety of valsartan and a combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension: a subgroup analysis of the effect of valsartan and its combination with hydrochlorothiazide on pulse wave velocity and central blood pressure
The efficacy and safety of valsartan and a combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension: a subgroup analysis of the effect of valsartan and its combination with hydrochlorothiazide on pulse wave velocity and central blood pressure // Kardiologia Polska, 76 (2018), 2; 328-337 doi:10.5603/KPa2017.0240 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1087424 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The efficacy and safety of valsartan and a
combination of valsartan and hydrochlorothiazide
in the treatment of patients with mild to
moderate arterial hypertension: a subgroup
analysis of the effect of valsartan and its
combination with hydrochlorothiazide on pulse wave
velocity and central blood pressure
Autori
Accetto, Rok ; Widimsky Jr, Jiri ; Vincelj, Josip ; Sirenko, Yuriy ; Chazova Yevgenyevna, Irina ; Barbić Žagar, Breda
Izvornik
Kardiologia Polska (0022-9032) 76
(2018), 2;
328-337
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Pulse wave analysis ; Antihypertensive agent ; Valsartan ; Clinical trial
(pulse wave analysis ; antihypertensive agent ; valsartan ; clinical trial)
Sažetak
The aim of the study was to establish the effect of valsartan and combination of valsartan and hydrochlorothiazide (HCTZ) od pulse wave velocity (PWV) and central blood pressure (CBP) in a large population of patients with mild to moderate arterial hypertension. This was an international, multicentre, open-label, prospective trial. After one week of washout in previously treated patients, 74 subjects were treated with valsartan or valsartan combined with HCTZ for 16 weeks according to the protocol. During the active treatment, four visits were planned for each patient to obtain data for the primary and secondary efficacy. At the beginning and at the end of the study PWV and CBP were determined with central arterial pressure waveform analysis (SphygmoCor, Atcor Medical). This study is registered with clinicaltrialsregister.eu, EudraCT number 2012-005129-57. The results of the present VICTIRY trial showed that valsartan and combination of valsartan and HCTZ effectively reduced the brachial blood pressure in patients with mild to moderate arterial hypertension as well as PWV, central systolic blood pressure and central diastolic blood pressure. The effects on the augmentation index were not statistically significant. Valsartan and valsartan/HCTZ improve arterial stiffness in patients with mild to moderate hypertension
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinička bolnica "Dubrava",
Medicinski fakultet, Osijek,
Sveučilište J. J. Strossmayera u Osijeku
Profili:
Josip Vincelj
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- EMBASE (Excerpta Medica)
- Index Copernicus
- EBSCO
- Cros Ref